<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657186</url>
  </required_header>
  <id_info>
    <org_study_id>TAR/006118</org_study_id>
    <nct_id>NCT03657186</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Benefit of ProbioSatys™ on Weight Reduction in Overweight Subjects</brief_title>
  <official_title>Double-blind, Randomised, Placebo-controlled Study to Evaluate Benefit of ProbioSatys™ on Weight Reduction in Overweight Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TargEDys</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Analyze &amp; Realize</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TargEDys</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the effects of ProbioSatys™ on body weight and related parameters
      in overweight subjects during a 12-week consumption period. In addition, tolerability and
      safety of ProbioSatys™ will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ProbioSatys™ is a probiotic nutritional solution containing a commensal Enterobacteriaceae
      food grade strain, Hafnia alvei 4597. The microbiome is known to play a crucial role in body
      weight management and metabolic disease. ProbioSatys™ mechanism of action relies on bacterial
      metabolites that send local and central signals via the gut-brain axis by molecularly
      mimicking satiety hormones involved in appetite regulation.

      Numerous ProbioSatys™pre-clinical studies indicate that consumption of the strain leads to
      body weight loss based on food intake reduction, but also improvement of body composition
      (increase of lean mass/fat mass ratio), and improvement of glucose metabolism (oral glucose
      tolerance test, and fasted glycemia).

      The present study aims to evaluate the effects of ProbioSatys™ on body weight and related
      parameters in overweight subjects during a 12-week consumption period. In addition,
      tolerability and safety of ProbioSatys™ will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2018</start_date>
  <completion_date type="Actual">November 28, 2019</completion_date>
  <primary_completion_date type="Actual">November 28, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who lost at least 3% of baseline body weight (=&quot;3% responders&quot;)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight change (in kg), compared to baseline (V2)</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight change (%), compared to baseline (V2)</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight (in kg )</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who lost at least 3% of baseline body weight (=&quot;3% responders&quot;)</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who lost at least 5% of baseline body weight (=&quot;5% responders&quot;)</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat mass assessed per bioelectrical impedance analysis (BIA), compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat free mass assessed per bioelectrical impedance analysis (BIA), compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference, compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip circumference, compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism parameters (total cholesterol), compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism parameters (high density lipid cholesterol), compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism parameters (low density lipid cholesterol), compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated haemoglobin (HbA1c), compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the overall feeling of satiety compared to baseline by using visual analogue scales (VAS)</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
    <description>continuous line between two endpoints: not saturated at all &amp; fully saturated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the overall feeling of fullness compared to baseline by using visual analogue scales (VAS)</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
    <description>continuous line between two endpoints: not full at all &amp; extremely full</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the overall feeling of craving compared to baseline by using a 5 point Likert scale</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
    <description>0= &quot;no&quot;, 1= &quot;slightly&quot;, 2= &quot;moderate&quot;, 3= &quot;strong&quot; and 4= &quot;very strong&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General well-being parameters (Impact of Weight on Quality of Life-Lite, IWQOL-LITE), compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global evaluation of benefit at V5 by subject and the investigator</measure>
    <time_frame>12 weeks</time_frame>
    <description>&quot;very good&quot;, &quot;good&quot;, &quot;moderate&quot; and &quot;poor&quot;</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of adverse events throughout the study</measure>
    <time_frame>14 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure, compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pulse rate, compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>analysis of full blood count parameters (haemoglobin)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>analysis of full blood count parameters (haematocrit)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>analysis of full blood count parameters (thrombocytes)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>analysis of full blood count parameters (leucocytes)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>liver and renal function parameters (alanine transaminase)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>liver and renal function parameters (aspartate aminotransferase)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>liver and renal function parameters (gamma-glutamyltransferase)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>liver and renal function parameters (alkaline phosphatase)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>liver and renal function parameters (bilirubin)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>liver and renal function parameters (creatinine)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>liver and renal function parameters (urea)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>liver and renal function parameters (uric acid)</description>
  </other_outcome>
  <other_outcome>
    <measure>Global evaluation of tolerability at V5 by subject and the investigator</measure>
    <time_frame>12 weeks</time_frame>
    <description>&quot;very good&quot;, &quot;good&quot;, &quot;moderate&quot; and &quot;poor&quot;</description>
  </other_outcome>
  <other_outcome>
    <measure>Gastrointestinal tolerability parameters (Gastrointestinal Symptom Rating Scale questionnaire, GSRS), compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stool frequency in the week before each visit post- baseline, each compared to the week before baseline (V2)</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity parameters (Global Physical Activity Questionnaire, GPAQ), compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">236</enrollment>
  <condition>Overweight</condition>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>ProbioSatys™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ProbioSatys™</intervention_name>
    <description>One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.</description>
    <arm_group_label>ProbioSatys™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to 65 years old males and females

          2. Overweight (Body Mass Index, BMI: 25 kg/m2 - 29.9 kg/m2)

          3. Generally in good health

          4. Desire to lose weight

          5. Regularly consuming 3 main meals/day (breakfast, lunch, dinner)

          6. Readiness to comply with study procedures, in particular:

               -  Follow diet recommendation

               -  Maintain the habitual level of physical activity during the study

               -  Fill out the questionnaires and subject diary

               -  Take the IP as instructed

          7. Stable body weight in the last 3 months prior to V1 (≤5% self-reported change)

          8. Stable concomitant medications (if any) for at least last 3 months prior to V1

          9. Women of childbearing potential:

               -  Negative pregnancy testing (beta HCG-test in urine) at V1

               -  Women of childbearing potential: commitment to use contraception methods (with
                  the exception of starting new contraception medication)

        Participation is based upon written informed consent form by the participant following
        written and oral information by the investigator regarding nature, purpose, consequences
        and possible risks of the clinical study.

        Randomisation criteria (to be checked after run-in at V2):

          1. No change in body weight or reduction up to 3 kg (compared to V1)

          2. Adequately completed subject diary

          3. Readiness and ability to comply with study requirements

          4. Relevant inclusion and exclusion criteria met

        Exclusion Criteria:

          1. Known allergy/sensitivity to any components of the investigational product

          2. Pathological electrocardiogram (ECG) at V1

          3. History and/or presence of clinically significant self-reported disorder as per
             investigator's judgement:

               -  Untreated or non-stabilised thyroid gland disorder

               -  Untreated or non-stabilised hypertension (regular systolic blood pressure ≥ 140
                  mmHg and/or diastolic blood pressure ≥ 90 mmHg)

               -  Digestion/absorption disorders of the gastrointestinal tract (e.g. inflammatory
                  bowel disease, coeliac disease, pancreatitis etc.) and/ or gastrointestinal
                  surgery

               -  Diabetes mellitus type 1 or untreated/non-stabilised type 2

               -  Acute or chronic psychotic disorder

               -  Immunodeficiency

               -  Any other organ or systemic diseases that could influence the conduct and/or
                  outcome of the study and/or could affect the tolerability of the subject

          4. History and/or presence of eating disorders like bulimia, anorexia nervosa,
             binge-eating as per investigator's judgement

          5. Any electronic medical implant

          6. Deviation of safety laboratory parameter(s) at V1 that is:

               -  Clinically significant or

               -  &gt;2x upper limit of normal, unless the deviation is justified by a previously
                  known not clinically relevant condition (e.g. Gilbert's syndrome)

          7. Use of medication/supplementation in the last month prior to V1 and during the study,
             as per investigator's judgement:

               -  That could influence gastrointestinal functions (such as antibiotics, probiotics,
                  laxatives, opioids, anticholinergics, anti-diarrheals etc.)

               -  For weight management (e.g. fat binder/burner, satiety products etc.)

               -  That could influence body weight (e.g. antidepressants, systemic corticoids etc.)

               -  That could otherwise interfere with study conduct / evaluation

          8. Diet/weight loss programs within the last 3 months prior to V1 and during the study

          9. Smoking cessation/modification of smoking level (if any) within 6 months prior to V1
             and/or during the study (regular smoking during the study at the same level as prior
             to the study is allowed)

         10. Vegetarian, vegan or other restrictive diet

         11. Pregnancy or nursing

         12. History of or current abuse of drugs, alcohol or medication

         13. Inability to comply with study procedures

         14. Participation in another study during the last 30 days prior to V1

         15. Any other reason deemed suitable for exclusion, per investigator's judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Analyze &amp; Realize</name>
      <address>
        <city>Berlin</city>
        <zip>10369</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Grube</name>
      <address>
        <city>Berlin</city>
        <zip>10709</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jörg Förstermann</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 2, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Hafnia alvei</keyword>
  <keyword>Overweight</keyword>
  <keyword>Food intake</keyword>
  <keyword>Appetite regulation</keyword>
  <keyword>Satiety</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Glucose Metabolism</keyword>
  <keyword>Glycemia</keyword>
  <keyword>Enterobacteriaceae</keyword>
  <keyword>Gut-brain axis</keyword>
  <keyword>Molecular mimicry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

